MacuSight's lead development program involves advancing sirolimus as a potential next-generation therapeutic for the treatment and prevention of wet age-related macular degeneration (wet AMD) and the treatment of diabetic macular edema (DME), a manifestation of diabetic retinopathy.

Sirolimus, originally known as rapamycin, is a molecule that was isolated in the mid-1970s from a bacterial strain found in a soil sample on Easter Island. The molecule's original name derives from the native name of Easter Island (Rapa Nui).

A highly-potent, broad-acting compound, sirolimus has demonstrated the ability to combat disease through multiple mechanisms of action including immunosuppressive, anti-angiogenic, anti-migratory, anti-proliferative and anti-fibrotic activity. The inherent versatility associated with these multiple mechanisms of action positions sirolimus as a potentially highly-efficacious therapeutic for a wide range of ocular diseases and conditions.

• Lead Program
• Mechanisms of Action
• Safety
• Optimized Administration
• Clinical Status
• Intellectual Property

"Sirolimus' inherent versatility positions the compound as a potential therapeutic for a wide range of ocular diseases and conditions."